csm_titel_studie_2017_18_0246661b5b.jpg

Danish microbiome specialist Clinical Microbiomics A/S has completed a €10m growth financing led by – Seventure Partners.

Photo from the kick-off meeting of the Youth-GEMS project. © University of Maastricht.

The EU Commission has granted £8.4m for Youth-GEMS, the largest ever study to identify genetic and other risks affecting mental health in adolescence.

Standing Ovation CEO Frédéric Paques (left)/impressions form the start-up pitch © BIOCOM AG

French Standing Ovation has won the start-up pitch of Industria Biotec, held for the first time in Berlin. The event presents biotechnological solutions to save the climate.

Araris' linker technology enables site-specific payload attachment to a specific amino acid (Q295) within the IgG-Fc framework. When a payload is attached to this site, the antibody still maintains nearly identical performance (e.g. pharmacokinetics and effector functions) to the unconjugated, original antibody. Furthermore, the linker-payload is connected to the antibody through a very strong peptide bond resulting in exceptional stability in the blood stream and thus minimal adverse effects. © Araris Biotech AG

Swiss ADC maker Araris Biotech AG has added a $24m financing round to its CHF15.2m (S17.8m) seed round in 2020 to expand its portfolio of proprietary antibody drug conjugates.

© Big Idea Ventures

With money from its $50m New Protein Fund, Big Idea Ventures funds in 17 pre-seed plant-based, cell-based and microbial food, ingredient and technology companies.

Part of Sybilla's team. © Sybilla Biotech

Verona-based Sibylla Biotech has closed a €23m Series A financing round to advance its Pharmacological Protein Inactivation by Folding Intermediate Targeting (PPI-FIT) platform.

© ppixabay/kalhh

Austrian XUND GmbH wants to use the assets of a €6m seed financing to grow in Germany, Switzerland and Austria.

Bertrand Damour, Chief Executive Officer of Pheon Therapeutics. © Pheon Therapeutics

Antibody-Drug Conjugate (ADC) specialist Pheon Therapeutics Ltd. has closed a $68m Series A financing co-led by Brandon Capital, Forbion and Atlas Venture.

Agonists of the innate immune system might turn cold to hot (inflamed) tumours. © Dana Farber Cancer Center

Kupando has raised €13m in Series A financing co-led by Remiges Ventures and LifeCare Partners to initiate clinical development of KUP101.

Inflamed joint © Laboratoires Servier

Danish AI health app developer DAMAN P/S has entered the €12m EU-funded Squeeze project, that aims to find stratification biomarkers for DMARDs in rheumatoid arthritis (RA).